Information Provided By:
Fly News Breaks for May 19, 2017
May 19, 2017 | 07:54 EDT
JMP Securities analyst Liisa Bayko started coverage of Spring Bank with a $20 price target and an Outperform rating. She says that Spring Bank's SB9 9200 drug could become "a backbone of HBV therapy," creating a multibillion dollar revenue stream for the company.
News For SBPH From the Last 2 Days
Jun 21, 2017 | 16:01 EDT
Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Spring Bank intends to use the net proceeds from this offering for continued development of its product candidates and general corporate purposes.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.